The viral vectors & plasmid DNA manufacturing market is pegged at more than US$ 1.3 Billion by the end of the forecast period 2020 to 2027 and is witness to grow highest CAGR of 14.08% from 2020 to 2027.
The report provides the overall revenue of the global viral vectors & plasmid DNA manufacturing market from 2016 to 2027, considering 2020 as the base year and 2027 as the forecast year.
Gene therapy is an experimental treatment that comprises incorporating genetic material inside a person’s cells to stop or fight a particular disease. Researchers are studying gene therapy for several diseases including hemophilia, cancer, Parkinson’s disease, severe combined immuno-deficiencies, HIV, via numerous dissimilar methods. A gene can be carried to a cell with the help of a carrier known as a vector. Viruses are the most general kinds of vectors used in gene therapy. Since last few years, several non-viral and viral vectors have been standardized and enhanced.
At present, the much wide spread viral vectors utilized for gene therapies are those based on lentivirus, retrovirus, adenovirus, and AAV vectors. These correspondingly form 8%, 16%, 20%, and 8% of the clinical trials of active gene therapy. Likewise, plasmid DNA has appeared as the most frequently preferred vectors amid non-viral gene delivery tools. Further, it finds application in production and development of DNA vaccines and viral vectors. There is growing demand for practical manufacturing solutions for viral vectors that can be freely scaled and boosted. This is because gene and cell therapies possess latent to quickly advance via clinical trials to commercialization. With the help of ongoing efforts, several organizations are respectively executing and developing state-of-the-art solutions intended to scale-up for viral vector manufacturing and speed up process development.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1012
Growth Factors
Viral vectors have become ideal choice for gene transfer due to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploited latent in emergent markets is projected to provide worthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies have exhibited favorable results. As a result of this, several investors are attracted towards this area which is making plasmid and viral vector manufacturing market a vigorous sector of investment. Further, it is inspiring fortunate funding activities from both the public and private sectors.
Report Highlights
- Presently, around two-thirds of the gene therapy research is dedicated to oncology. These different facts have backed the governance of cancer segment over other disease segments
- Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies
- Pharmaceutical and biopharmaceutical companies are expected to collect major share of the global vector market. This is because of the effective launch of viral vector gene therapies and a vigorous pipeline of such therapies that helps growth of pharmaceutical and biopharmaceutical companies during near future.
- Presently, U.S. and Europe have seemed as vector manufacturing centers despite of the fact that the first 3 gene therapy candidates were granted in Asian countries
Regional Snapshots
About 68% of the total international active clinical studies for gene therapies are proceeding in North America despite of the fact that the first 3 gene therapy candidates (Oncorine®, Gendicine® andRexin-G®) were accepted in Asia Pacific. During coming years, Asia Pacific is anticipated to grow at the fastest pace viral vector manufacturing market. Spurring research activities to unveil innovative gene therapies in the unexploited markets of this region are projected to support this tremendous growth in near future.
Key Players & Strategies
Several established organizations have been involved in the production of vectors since the inception of this domain. However, the growing demand for these programs has spurred the establishment of many start-ups as well. Examples include (indicative list, in alphabetical order) Batavia Biosciences, Brammer Bio, GenIBET Biopharmaceuticals, Immune Technology, Lentigen Technology, Luminous Biosciences, Oxford Genetics, SignaGen Laboratories, Vectalys and Virovek. It is also worth highlighting that over 50 academic institutes / non-profit organizations are currently involved in the production of vectors for use in gene therapies.
The demand for clinical grade and research vectors is much than commercial grade vectors and almost many gene therapy entrants are in development stage. Nevertheless, some companies have are rigorously manufacturing commercial scale capacity for vector production.
Some of the significant players in the viral vectors & plasmid DNA manufacturing market include:
- Novasep
- Aldevron
- MerckWaismanBiomanufacturing
- Creative Biogene
- The Cell and Gene Therapy Catapult
- Cobra Biologics
- uniQure N.V.
- Addgene
- FUJIFILM Holdings Corporation
- Oxford Biomedicaplc
- Takara Bio Inc.
Segments Covered in the Report
This research report estimates revenue growth at global, regional, and country levels and offers an analysis of present industry trends in everysub-segment from 2016 to 2027. This research study analyzes market thoroughly by classifying global viral vectors & plasmid DNA manufacturing market report on the basis of different parameters including type of vector, application, workflow, end users, disease, and region:
By Vector Type
- Adenovirus
- Plasmid DNA
- Lentivirus
- Retrovirus
- AAV
- Others
By Application
- Gene Therapy
- Antisense &RNAi
- Cell Therapy
- Vaccinology
By Workflow
- Upstream Processing
- Vector Recovery/Harvesting
- Vector Amplification & Expansion
- Downstream Processing
- Fill-finish
- Purification
By End-User
- Biopharmaceutical and Pharmaceutical Companies
- Research Institutes
By Disease
- Genetic Disorders
- Cancer
- Infectious Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Click Here to Browse Full Report Table of Contents
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Why Buy this Report?
The purpose of Precedence Research’s viral vectors & plasmid DNA manufacturing market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1012
About Us
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://precedenceresearchnews.wordpress.com
The post Viral Vectors & Plasmid DNA Manufacturing Market To Grow At Rate Of 14.08% Through 2027 appeared first on Flair Insight.
